Catalyst in the News

11/13/08 — SynapseSynapse reports that vigabatrin, which Catalyst is testing as an addiction treatment, blocks reinstatement of drug-seeking behavior in animals, giving hope for treating relapse to methamphetamine abuse.
Featured News8/20/08 — SynapseSynapse reports that genetically bred “fat rats” given vigabatrin, which Catalyst is testing as an addiction treatment, experience dramatic weight loss.
Featured News7/14/08 — KENS-TV, video reportEyewitness News of San Antonio, Texas, CBS affiliate KENS-TV, ran a report on Catalyst’s cocaine trial featuring a participant at the University of Texas Health Science Center.
3/3/08 — Newsweek (PDF version) Cover story: "What Addicts Need: Addiction isn't a weakness; it's an illness. Now vaccines and other new drugs may change the way we treat it."

12/18/07 — Rodman & Renshaw, transcript (PDF)
Rodman & Renshaw rates Catalyst "Market Outperform" and sponsors expert panel on the promise of vigabatrin to treat addiction.
12/07 — The Ones to Watch (PDF)
In its quarterly review, Thomson Scientific calls CPP-109 one of "the five most promising drugs entering Phase II trials" from July to September 2007. See page 7
07/16/07 — BioCentury
"Product Development: Down-sizing the High"
07/05/07 — TIME magazine
"How We Get Addicted"
02/16/07 — Long Island Newsday
"Dulling dopamine's kick"
01/14/07 — Miami Herald
"Catalyst focuses on drug to treat addicts"

04/21/05 — Senate Testimony
Nora D. Volkow, MD, Director of NIDA, discusses promise of CPP-109 during "Methamphetamine Abuse – Testimony before the Senate Subcommittee on Labor, Health and Human Services, Education, and Related Agencies – Committee on Appropriations"

12/10/04 — VentureWire Lifescience
"Catalyst Looks for $10M Series B as it Plans Clinical Trials"
02/15/04 — NIDA Notes
"The Long Road to Medication Development: Cocaine Treatment Moves to Clinical Trials"